<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36890">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02002221</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A1405</org_study_id>
    <nct_id>NCT02002221</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients</brief_title>
  <official_title>A 12-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Equa (Vildagliptin) 50 mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of vildagliptin 50 mg bid
      add-on therapy to improve overall glycemic control in patients with T2DM inadequately
      controlled by insulin, with or without concomitant metformin treatment. It was agreed with
      PMDA to conduct a postmarketing clinical trial to further collect the efficacy and safety
      data of vildagliptin especially in Japanese patients when it is used on top of insulin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in glycosylated hemoglobin (HbA1c) at 12 weeks between treatment groups</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>HbA1c will be performed on a blood sample obtained and measured by HPLC performed at a central laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients meeting Responder rates in HbA1c</measure>
    <time_frame>Baseline, at 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Responder rates will be analyzed in categories: a.Endpoint HbA1c ≤ 6.5% b.Endpoint HbA1c &lt; 7% c.Endpoint HbA1c &lt; 7% in patients with baseline HbA1c ≤ 8% d.HbA1c reduction from baseline at endpoint ≥ 1% e.HbA1c reduction from baseline at endpoint ≥ 0.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Fasting plasma glucose (FPG) at 12 weeks</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>FPG will be performed on a blood sample obtained and analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with hypoglycemia and sever hypoglycemia</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>symptoms consistent with hypoglycemia and confirmed by plasma glucose &lt; 56 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events, serious adverse events and death</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The occurrence of adverse events will be sought by non-directive questioning of the patient at each visit. Adverse events are defined as appearance or worsening of any undesirable symptom, vital sign, or medical conditions. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>LAF237</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vildagliptin 50 mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vildagliptin 50 mg matching placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAF237 50 mg</intervention_name>
    <description>Corresponds to vildagliptin 50 mg twice daily</description>
    <arm_group_label>LAF237</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo of vildagliptin 50 mg twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of T2DM by standard criteria.

          -  HbA1c ≥ 7.0 to ≤ 10% at Visit 1.

          -  Age: ≥ 20 to &lt; 75 years old at Visit 1.

          -  BMI ≥ 20 to ≤ 35 kg/m2 at Visit 1.

        Exclusion Criteria:

          -  FPG ≥ 270 mg/dL (≥15 mmol/L) at Visit 1.

          -  Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or
             secondary forms of diabetes.

          -  Significant heart diseases

          -  Hepatic disorder

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+81337978748</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Funabashi-city</city>
        <state>Chiba</state>
        <zip>274-0805</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>810-8798</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukutsu-city</city>
        <state>Fukuoka</state>
        <zip>811-3217</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu-city</city>
        <state>Fukuoka</state>
        <zip>800-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ibusuki-city</city>
        <state>Kagoshima</state>
        <zip>891-0401</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>221-0802</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kumamoto-city</city>
        <state>Kumamoto</state>
        <zip>861-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>615-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hirakata-City</city>
        <state>Osaka</state>
        <zip>573-0153</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Takatsuki-city</city>
        <state>Osaka</state>
        <zip>569-1096</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ageo-city</city>
        <state>Saitama</state>
        <zip>362-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sayama-city</city>
        <state>Saitama</state>
        <zip>350-1305</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokorozawa-city</city>
        <state>Saitama</state>
        <zip>359-1161</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nerima-ku</city>
        <state>Tokyo</state>
        <zip>177-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nerima-ku</city>
        <state>Tokyo</state>
        <zip>177-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>144-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>November 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
